Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment
Blood (2019) 134 (Supplement_1): 581.
Currently there are no citedby results. Try again later.
